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Abstract
Background: There is strong evidence to support the effectiveness of Brief Intervention (BI) in reducing alcohol
consumption in primary healthcare.
Methods and design: This study is a two-arm randomised controlled trial to determine the effectiveness of BI
delivered by community pharmacists in their pharmacies. Eligible and consenting participants (aged 18 years or
older) will be randomised in equal numbers to either a BI delivered by 17 community pharmacists or a non-
intervention control condition. The intervention will be a brief motivational discussion to support a reduction in
alcohol consumption and will take approximately 10 minutes to deliver. Participants randomised to the control arm
will be given an alcohol information leaflet with no opportunity for discussion. Study pharmacists will be volunteers
who respond to an invitation to participate, sent to all community pharmacists in the London borough of
Hammersmith and Fulham. Participating pharmacists will receive 7 hours training on trial procedures and the
delivery of BI. Pharmacy support staff will also receive training (4 hours) on how to approach and inform pharmacy
customers about the study, with formal trial recruitment undertaken by the pharmacist in a consultation room. At
three month follow up, alcohol consumption and related problems will be assessed with the Alcohol Use Disorders
Identification Test (AUDIT) administered by telephone.
Discussion: The UK Department of Health’s stated aim is to involve community pharmacists in the delivery of BI to
reduce alcohol harms. This will be the first RCT study to assess the effectiveness of BI delivered by community
pharmacists. Given this policy context, it is pragmatic in design.
Trial registration: Current Controlled Trials ISRCTN95216873
Keywords: Alcohol, Brief intervention, Community pharmacist, Community pharmacy, Hazardous and harmful drinking
Background
In the UK alcohol misuse leads to an estimated cost to
society of £25.1 billion per annum (NHS costs £2.7 billion)
and is the third leading cause of ill health [1]. Population-
level interventions that seek to influence the price, avail-
ability and cultural acceptability of heavy drinking are
likely to be most effective in reducing these problems [2].
These may be complemented by individual-level inter-
ventions delivered in health services and elsewhere. The
UK Department of Health aims to involve community
pharmacists in delivering alcohol brief interventions [3].
It has recommended that pharmacy based alcohol inter-
ventions should be piloted and evaluated.
Brief interventions are discussions which seek to change
views of the personal acceptability of excessive drinking
and to encourage self-directed behaviour change. They in-
clude simple forms of structured advice and brief counsel-
ling. Typically, questions about alcohol use are asked to
motivate the person to take action to change drinking
where this may be beneficial [4]. There is strong evidence
to support the effectiveness of BI to reduce alcohol con-
sumption in primary healthcare [5]. In 21 randomised
controlled trials conducted in primary health care settings
with 7,286 participants, those who received BI reduced
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their alcohol consumption by 41 grams/week (five U.K.
units of alcohol) on average compared to those who did
not receive BI [5]. However there are no trials which have
assessed the effectiveness of BI delivered in the commu-
nity pharmacy setting.
It is useful to think of three types of drinking that are
injurious to health: a) Hazardous drinking (which carries
a risk of harmful consequences to the drinker for ex-
ample occasional binge drinking); b) Harmful drinking
(pattern of drinking already causing psychological or
physical damage to health) and c) Dependent drinking
(which may benefit from specialist intervention) [1]. The
World Health Organisation (W.H.O) 10-item Alcohol
Use Disorder Identification Test (AUDIT) screening tool
has been extensively validated in identifying those whose
drinking is hazardous or harmful, including those who
are dependent [6-8].
Guided by the Medical Research Council (MRC) frame-
work for developing and evaluating complex interventions
[9], the design of this trial has been informed by our previ-
ous studies assessing pharmacy customers’ perceptions
and the feasibility of BI in community pharmacies [10,11]
and studies that recommend establishing the acceptabil-
ity of discussing alcohol use in health care settings [12].
Our NHS Westminster study which assessed 102 phar-
macy customers perceptions of BI established that most
customers (N = 97, 96%) would find it acceptable to
discuss their drinking with the pharmacist [10]. Our
uncontrolled before and after study of BI in community
pharmacies in Lambeth involved training 29 community
pharmacists in BI and monitoring change in drinking
among a cohort of service users [11]. Experiences of receiv-
ing the service, and the barriers and enablers experienced
by study pharmacists were also assessed. A key finding of
this study was that pharmacists unfamiliar with BI could
be trained to deliver alcohol interventions. In addition in-
volving support staff to inform pharmacy customers about
BI and providing regular support to pharmacy staff were
found to be important factors in achieving high BI delivery
rates in community pharmacies.
This trial builds on previous research undertaken by
others, including a questionnaire study in New Zealand
exploring attitudes, knowledge and experiences of 101
community pharmacists. These pharmacists reported being
motivated to take up BI but expressed a lack of confidence,
knowledge and skills to advise customers on their drinking
[13]. A larger study conducted in New Zealand (2383
customers at 43 pharmacies), also suggested that customers
were positive about being offered BI from pharmacies [14].
There has been one published discussion paper assessing
the feasibility of BI conducted by community pharmacists
in the UK [15]. The three feasibility studies discussed in
this review (all U.K. cities: London; Glasgow; and Leeds)
included a total of 14 pharmacies and 500 customers,
from which 30% to 53% were identified as drinking
above the UK recommended levels (i.e. women drinking
more than 24 grams of ethanol/day and men more than
32 grams of ethanol/day [1]. The authors in the discus-
sion paper supported the feasibility of BI delivered in
community pharmacies and noted that there had been
“little empirical evaluation of the effectiveness of com-
munity pharmacy-based services for alcohol misuse”,
concluding that large scale effectiveness studies were
now needed [15].
Aim
To determine if alcohol BI delivered by community
pharmacists is effective at reducing hazardous and harm-
ful drinking among pharmacy customers at three-month
follow-up compared to a non-intervention leaflet-only
control condition.
Objectives
 To identify the pharmacy use and demographic
profiles of participants recruited to the trial and
pharmacy customers who did not fulfil study
inclusion criteria or who refused.
 To determine rates of recruitment, refusal and
retention among pharmacy customers who are
approached to enter the trial.
 To conduct a randomised controlled trial of the
effectiveness of alcohol BI for hazardous and
harmful drinkers accessing community pharmacy
services within NHS Hammersmith and Fulham,
London, UK.
 To assess differences in risky drinking and general
health status between BI and control participants
after three-months.
 To determine participants’ experience of
participating in this trial.
Method and design
Trial design
This study is a two arm randomised controlled trial
(Figure 1). Pharmacy customers who have consented to
participate in the trial will have their alcohol risk assessed
using the AUDIT [6]. The target population are hazardous
and harmful drinkers scoring 8 or over and less than 20
(at which score it is recommended that alcohol depend-
ence be assessed).
Participants
Setting
The London borough of Hammersmith and Fulham has a
population of 177100, which comprises a high proportion
of young adults (45% in their 20’s and 30’s) and is ethnic-
ally diverse [16]. There are 40 community pharmacies
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within Hammersmith and Fulham [17], of which 37 pro-
vide a smoking cessation service, 14 supervised consump-
tion service of controlled medications (e.g. methadone) and
11 provide a needle exchange service [17]. Local needs as-
sessment suggests that 31.5% (N = 45914) of Hammersmith
and Fulham residents are hazardous or harmful drinkers
and have the highest rates of harmful and binge drinking
behaviour in London [16].
Sample size
Sample size consideration was based on a meta analytic ef-
fect size of 0.30 in non-treatment seeking samples at
three-month follow-up in the review of brief interventions
across settings undertaken by Moyer and colleagues [18].
Using G Power computer programme [19], requiring 80%
power in a one-tailed power calculation with alpha = 0.05,
139 participants per group would be required to detect an
effect of this magnitude. Allowing for 30% attrition at
three months, 199 participants per group will be recruited
(a total of 398 trial participants).
Findings from a preliminary study identified that 41%
(N = 98) of pharmacy customers approached to partici-
pate in a survey were willing to accept anonymous
screening of their alcohol use [10]. We conservatively
estimated that approximately 6032 pharmacy customers
would need to be approached and invited to participate,
for 2473 to agree to be screened. Based on findings from
previous feasibility studies [11,15,20] we expect approxi-
mately 44% (N = 1088) to be identified as risky drinkers
with the Single Alcohol Screening Question (SASQ;
see below) preliminary screen. We estimate that 50%
(N = 544) of those who screen positive will consent to
Figure 1 Study design. Measures used with trial participants and the stage that they are administered.
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participate in the study and that 25% (N =136) of these
will be found not to be eligible when the AUDIT is
administered in the second stage of the procedure.
Sample size estimates at each stage of the recruitment
process for a projected final N = 408 are presented in
Figure 2.
Community pharmacist recruitment
Pharmacists practicing in community pharmacies within
Hammersmith and Fulham, with an NHS contract and a
private consultation room will be invited to participate.
Pharmacists will be contacted initially by letter and tele-
phone. Following this, personal pharmacy visits will be
arranged to enable the Chief Investigator (RD) to provide
information on the trial, obtain pharmacists’ consent and
arrange suitable training dates. A total of 17 pharmacists
will be recruited for the study. Pharmacy support staff
working with recruited pharmacists will be invited to attend
a brief training session on how to inform and identify suit-
able participants for the trial.
Figure 2 Study participant recruitment. Expected number of pharmacy customers to be: approached, assessed for eligibility, recruited to the
trial, allocated an intervention or control condition and followed up for analysis.
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Participant recruitment
Pharmacy customers will be informed about the study
by pharmacy staff if they are observed performing any of
the following activities: a) viewing study posters and
flyers displayed within the pharmacy counter area; b)
making a general health query or seeking advice which
could be linked to alcohol use; c) purchasing pharmacy
over the counter products for smoking cessation aids,
gastrointestinal remedies, sleep aids and central nervous
system depressants (listed in the current edition of the
Medicine Chest directory [21] d) receiving any of the
following pharmacy services: Smoking Cessation, Medi-
cation Use Review, Health Check or Emergency Hormonal
Contraception; e) presenting prescriptions for medications
for any of the following conditions: cardiovascular disease,
depression or anxiety, diabetes or gastric problems.
Records of number of customers informed about the
study but who refuse to participate or do not fulfil the
study criteria will be kept. Anonymous information on
customers’ gender, activity in the pharmacy, reason given
for not participating and the date they visited the phar-
macy will be recorded. Customers will have the content
of the Participant Information Sheet explained by phar-
macy staff and be given a copy to keep and be asked a
Single Alcohol Screening Question (SASQ), “How often
do you have three or more drinks on a single occasion?”
This question was adapted for this trial and is based on
the previously validated SASQ [22,23]. We are aware
that such brief screeners have their limitations and thus
we used a two stage eligibility procedure [24]. Customers
who are administered the SASQ and report consuming
three or more drinks monthly or more regularly will be
invited to have their alcohol use assessed further using
the AUDIT by the pharmacist in the consultation room.
Participants who fulfil the study criteria and are willing
to participate in the trial will sign two copies of the con-
sent form with the pharmacist in the consultation room
and will be given one copy to keep.
Selection criteria
People aged 18 years or over accessing pharmacy services
within the participating pharmacies located in NHS
Hammersmith and Fulham who: a) have AUDIT scores
between 8–19 inclusive; b) are contactable by phone
during the study; c) have a home address in the UK;
and d) are able to speak, read and write in English are
eligible to take part in the study. Excluded are those
who are: a) currently in treatment for alcohol problems;
b) currently involved in any other alcohol research; and
c) employees of the trial pharmacies.
Pharmacy customers will thus be excluded if they are
identified as being possibly alcohol dependent (AUDIT
score ≥ 20). This group will be advised to see their GP and
be given a letter, with their AUDIT assessment result, to
take to their GP. Pharmacy customers who are identified
as low risk drinkers (AUDIT ≤ 7) will also be excluded
from the study. Both excluded groups will be given, “Units
and You” booklet [25], a “Unit/Calorie Calculator Wheel”
[26] and an alcohol services leaflet developed for the study
to take away.
Interventions
Brief intervention
Participants allocated to the Brief Intervention (BI) condi-
tion will be offered a discussion of approximately 10 -
minutes duration [4]. This intervention contains a number
of structured components in the form of an intervention
protocol. The conversation begins by building rapport
through asking questions about participants’ experience
of answering the AUDIT screening questions. Participants
are then encouraged to talk about how drinking fits in
with their lives, explore any ambivalence and elicit their
evaluation of their drinking including any problems
associated with it. The conversation will close by either
the participant or the pharmacist providing a summary
of the conversation. See Additional file 1: Appendix A
for the brief intervention protocol.
All trial pharmacists will be trained over half a day in
the intervention protocol including flexible use of these
discussion topics in ways influenced by the counselling ap-
proach of Motivational Interviewing [27]. A two hour
evening follow-up session will also be scheduled shortly
after the start of the trial. The purpose of the BI is to en-
courage participants to think further about their drinking
and whether they should reduce it, and if they are ready to
do so, to discuss how. It should be emphasised here that
the pharmacists will not be trained in Motivational
Interviewing, for which learning of skills cannot take
place in such brief training workshops alone [28] This
group will also be given the “Units and You” booklet
[25], a “Unit/Calorie Calculator Wheel” [26] and an al-
cohol services leaflet to take away.
Control condition
Participants allocated to the control condition will not be
explicitly informed that they are control participants. They
will be given a leaflet entitled “Alcohol: The Basics” which
includes information about alcohol. The leaflet content is
not expected to be effective at promoting behaviour
change [29].
Outcomes
Primary outcomes
 Change in AUDIT scores between trial recruitment
and follow-up.
 Proportion of hazardous and harmful drinkers
(scoring 8 or higher on AUDIT) at follow-up.
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Secondary outcomes
 AUDIT consumption subscale score.
 AUDIT problems subscale score.
 AUDIT dependence subscale score.
 General health status assessed using EQ-5D [30].
Data collection
Additional trial web pages have been developed and
incorporated into the existing online system for pharmacists
to record trial data [31]. The research team will have access
to trial data by using secure usernames and passwords
created for the trial. This online system has several
advantages over the paper-pen method. RD will have ac-
cess to pharmacy participants’ details as soon as each
participant is randomised and the visit to the pharmacy
completed; this will allow follow-up telephone calls to be
made promptly and avoid delays caused by physically
collecting completed trial paperwork from pharmacies. Ac-
cess to randomisation status and baseline data is prevented.
The system requires pharmacists to complete all fields cor-
rectly before proceeding to the next step, ensuring trial data
are complete. Data can also be accessed without revealing
randomisation status.
RD will arrange two telephone calls with study partic-
ipants. During both calls the researcher will be blind to the
participants’ intervention condition. The first telephone call
will be made within two weeks of recruitment and will take
between two to three minutes to complete. The purpose of
this call will be to make personal contact to confirm contact
details, gather additional tracing information as necessary
and to arrange the follow-up study telephone call three-
months post randomisation. Structured interview schedules
will be used to ensure all participants are asked the same
questions in a consistent manner in both calls. The primary
and secondary outcomes specified above will be collected
in the follow-up study telephone call after three months.
This will take approximately 15 minutes to complete and
participants will receive £10 gift voucher as a token of ap-
preciation for completing the second call.
Randomisation
Sequence generation We expect each pharmacist to re-
cruit 24 participants on average over a period of approxi-
mately 6 months, with equivalent numbers of intervention
(N = 12) and control (N = 12) participants randomised for
each pharmacist. The random sequence was generated in
blocks of 12 (BI = 6, Control = 6) with an Excel program,
with further blocks of the same size generated for those
who recruited more participants.
Allocation concealment mechanism Only after the
pharmacist has opened a sealed numbered envelope will
randomisation status be revealed. Neither pharmacists
nor pharmacy support staff will be able to subvert ran-
domisation and choose which participant will receive BI
if this process is implemented as designed. This will be
monitored during pharmacy visits, when RD will check
the sealed envelopes for evidence of tampering and that
the envelopes have been opened in numerical order, and
also by checking the integrity of the blocks via the online
data entry system. In addition, pharmacists will receive
training on the importance of following trial procedures.
Blinding
Pharmacists will be blind to allocation status until the
point at which they open the sealed envelope. Thereafter
they are not involved in research data collection. For the
purposes of both follow-up study and data management
relevant personnel will be blinded to randomisation sta-
tus throughout the trial.
Statistical methods
The data will be analysed on an intention to treat basis.
For outcome measures t-tests or Mann–Whitney tests
will be used for continuous data and chi-square tests
used for categorical data. If possible confounding is
identified, ANCOVA and logistic regression will be used
to examine the effect of the interventions over and above
these other factors, and effect sizes and odds ratios
calculated. For all tests, if necessary, measures will be
transformed before analysis. All analyses not conforming to
an a priori statistical plan will be declared as exploratory.
Sub-study
Participants who have consented to participate in a sub-
study, on their experience of participating in the trial,
will be randomly selected to be telephoned (N = 24).
Consent for this will be obtained alongside consent to
participate in the trial, i.e. in the consultation room with
the pharmacist. They will be contacted approximately
one month after the three-month follow-up telephone
call by RD for a 20 minute discussion by telephone. A
semi-structured topic guide developed for the study will
be used to explore participants’ experience. The tele-
phone interviews will be recorded using a digital voice
recorder, transcribed verbatim, data managed using a
qualitative research program [32] and analysed. Those
who have completed the telephone interview will be
sent a £10 gift voucher as a token of appreciation for
participation.
Ethical and research governance approval
This study has been given a favourable ethical opinion
(on 12th December 2011, REC reference: 11/LO/1448)
by the NRES Committee London- Queen Square, UK.
NHS Permission was granted by The West London Pri-
mary Care Consortium (for Research and Innovation) on
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behalf of NHS Hammersmith and Fulham (Primary Care
Trust) on 19th March 2012, NIHR CSP number: 11839.
Discussion
The UK Department of Health’s stated aim is to involve
community pharmacists in the delivery of BI to reduce
alcohol harms [3]. This will be the first RCT study to as-
sess the effectiveness of BI delivered by community
pharmacists and given this policy context, it is prag-
matic in design. This setting attracts hazardous and
harmful drinkers who are accessing community phar-
macy services. There are minimal exclusion criteria, for
example by not excluding those with co-morbidities, so
the study population is similar as possible to those BIs
would be delivered to if found to be effective.
The time available for pharmacists’ training (a morning
on trial procedures and an afternoon on BI delivery with
additional provision for a two hour evening follow-up)
was negotiated mindful of time pressures and other
commitments. Pharmacists will be reimbursed for their
one day of training, and given a modest fee given for
each trial participant. Similarly the duration of the BI
has been tailored to the time available for interventions
delivery in community pharmacies.
One possible consequence of these study design decisions
is that a null finding may result because the effect of BI has
been diluted by these study characteristics. We do not an-
ticipate that setting-specific factors will interfere with inter-
vention conduct, and the capacity of pharmacists to deliver
BIs effectively is what we are studying. Although the pri-
mary care evidence-base is well established, there are many
important questions about BI effectiveness that remain to
be addressed [33,34]. An evaluation of a stronger interven-
tion or with more extended training and skills development
inputs may show greater effectiveness and an efficacy trial
may show more promise. We are aware of these possibil-
ities and have made our study design decisions as we judge
most appropriate in the policy context described. If the trial
produces evidence of effectiveness then it will be appropri-
ate to subsequently undertake a large multi-centre trial
evaluating the effectiveness and cost-effectiveness of this BI
model to inform decision-making about the delivery of BIs
in pharmacies nationally.
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